imetelstat
geron corporation
['imerge', 'mds']
congress #eha2023 | presents imerge phase 3 results of imetelstat in heavily transfusion dependent lr-mds pts. primary endpoint was met; 39.8% vs 15.0% imetelstat- vs placebo-treated pts achieved 8-wk ti. no new safety signals observed.
#mds #mdssm 
Lifting levels of knowledge in myelodysplastic syndromes (#MDS). A global online platform providing latest treatment options and medical information. #mdssm